Amy Kelly, NP
Adult Health · Sumter, SCNPI 1578173555
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 212 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AstraZeneca at 27.2% of the total. 2025 is the largest year on record at $2,057, 2.9 times the $706 reported in 2021.
Across 212 payments — averaging $27.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Sanofi$843
- GSK$780
- Regeneron Healthcare Solutions, Inc.$728
- Boehringer Ingelheim$310
- Insmed, Inc.$292
- plus $1K from 23 others
What the payments were for
- Food & beverage$5,64597%
- Education$1923%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $1,588 |
| Sanofi | 22 | $843 |
| GSK | 33 | $780 |
| Regeneron Healthcare Solutions, Inc. | 21 | $728 |
| Boehringer Ingelheim | 15 | $310 |
| Insmed, Inc. | 13 | $292 |
| Philips North America LLC | 9 | $144 |
| Pulmonx Corporation | 1 | $143 |
| Amgen | 6 | $135 |
| United Therapeutics Corporation | 5 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $131 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Baxter Healthcare | 2 | $56 |
| Mylan Specialty L.p. | 3 | $51 |
| Actelion Pharmaceuticals US, Inc. | 2 | $50 |
| UCB, Inc. | 2 | $49 |
| AbbVie | 2 | $48 |
| Gilead | 2 | $41 |
| Genentech USA, Inc. | 2 | $34 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Viatris Specialty LLC | 1 | $23 |
| Verona Pharma, Inc. | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $21 |
| Argenx US, Inc. | 1 | $21 |
| Phadia US Inc. | 1 | $16 |
| Livanova USA, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Braintree Laboratories, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$227
- DUPIXENT$150
- CHARTIS CATHETER$143
- ZEPHYR DELIVERY CATHETER$143
- ZEPHYR ENDOBRONCHIAL VALVE$143
- PULMONX CHARTIS TABLET CONSOLE$143
- TEZSPIRE$120
- FASENRA$120
- BREZTRI$120
- TRELEGY ELLIPTA$111
How this compares
$5,837 in reported general payments places this provider in the 85th percentile of 292 adult health providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 368 | $289,237 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 175 | $128,696 |
| Spiriva RespimatTiotropium Bromide | 94 | $75,233 |
| Fasenra PenBenralizumab | 11 | $62,467 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 68 | $37,265 |
| Breo ElliptaFluticasone/Vilanterol | 63 | $26,326 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 135 | $24,796 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 28 | $20,741 |
| SymbicortBudesonide/Formoterol Fumarate | 55 | $16,569 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 471 | $14,965 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 32 | $14,000 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $12,953 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 25 | $12,753 |
| DuleraMometasone/Formoterol | 36 | $12,562 |
| Wixela InhubFluticasone Propion/Salmeterol | 65 | $9,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $780 | $370,137546 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,588 | $159,265262 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $310 | $108,727147 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 292 adult health providers in South Carolina.
Other adult health in Sumter
- Mary BairdSumter$10K
- Karen RobertsonGreenville$69K
- Christine FranzeseTega Cay$30K
- Jessica RiceGreenville$15K
- Michelle PriceCharleston$13K
- Melissa McCarterSpartanburg$12K
- Andrea OlsonWest Columbia$12K
- Jennifer BrittIrmo$11K
- Nichole SnowSpartanburg$10K
- Christi WigginsWest Columbia$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.